Predicting the Immune Response with NeoScreen®
Are you searching for Neo-Epitopes?
Our unique NeoScreen® Assay allows you to identify top neo-epitope candidates.
SARS-CoV-2 Vaccine Efforts
Immunitrack is committed to playing a role in the fight against COVID-19 by applying our epitope immunogenicity prediction technology to support vaccine development.
Our aim is to help our customers predict the immune response. Immunogenicity prediction is a key need in the field of biologics, particularly for cancer vaccines. We want to help our customers to identify “real” epitopes (those that will cause a T-cell response) from pools of potential neo-epitopes generated by sequencing data.
Conversely (e.g., protein/peptide-based therapeutics), there is often a need to predict if an unwanted immune response can occur.Watch video
Reagents – Order online!
When you’re investigating the immune response, you need reagents you can rely on.
Immunitrack has an extensive list of the most common MHC/epitope reagents both monomers and tetramers, as well as FcRn. Click on the category of interest to find out more.
Immunitrack proposes also the production of customized MHC I & II reagents as well as MHC binding assays on request. Contact us on firstname.lastname@example.org to discuss projects.
Immunitrack to Present Its Response to the COVID-19 Crisis At Embassy EventRead More
Immunitrack Sponsors and Participates in Immuno Series UK 2020 Virtual EventRead More
Immunitrack selected to be part of the InvestHorizon accelerator programRead More
COVID-19 Update: Immunitrack Expands SARS-CoV-2 Vaccine EffortsRead More
Moving Biologics Discovery Forward
Immunitrack has a stellar reputation in the field of peptide-MHC manufacture. Communication was prompt and clear. Our MHC tetramers arrived within a short timeframe. This allowed us to do faster iterations on our project.
Immunologist Biotech Company, California
Novozymes Biopharma uses the FcRn from Immunitrack to develop the albumin based half-life extension platform Veltis®. We have tested a number of commercially available FcRn’s in our screening assay developed for identification of albumin variants with improved affinity for FcRn receptor and found that the biotinylated FcRn’s from Immunitrack deliver superior performance. These biotinylated FcRn’s enable a robust immobilization to Streptavidin-biosensors (Octet Red96 from Pall ForteBio) and deliver very consistent and robust data.
Birgitte Andersen Science manager, Novozymes